Orchestra BioMed Holdings Inc. (OBIO)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Orchestra BioMed Holdings Inc..
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 3 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 4.10 $ — 57% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/04/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AAQS
1/10The AAQS (AlleAktien Quality Score) checks 10 quality criteria on growth, profitability, and balance-sheet strength — per the methodology developed and published by AlleAktien, calculated by us from our own fundamental data. A stock counts as a quality stock from 9 out of 10 points. Where a company has a shorter listing history, we calculate over the fiscal years available (at least five).
- Sales growth 10Y > 5% –
- Exp. sales growth 3Y > 5% –
- EBIT growth 10Y > 5% –
- Exp. EBIT growth 3Y > 5% –
- Net debt < 4x EBIT –
- EBIT positive, 10Y straight –
- Max. EBIT decline < 50% –
- Return on equity > 15% –
- ROCE > 15% –
- Expected return > 10% –
View all AAQS quality stocks · Read the methodology at AlleAktien
Source: fundamental data
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Growth Score
7 of 10 Solid growthTen checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years 111.6% passed
- More than 10% revenue growth is expected for the coming year 38.8% passed
- Share count grows by less than 3% a year 14.7% failed
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") 1,021.5% passed
- Gross margin at 40% or higher and without meaningful erosion 99.4% passed
- Goodwill from acquisitions does not grow faster than revenue 0.0% passed
- Net debt below twice EBITDA 91 m net cash passed
- Operating cash flow covers the profits of the last three years 17 m failed
- Return on capital at 15% or higher, or up versus two years ago -52.8% failed
- Insiders hold at least 10% or are net buyers 26.1% passed
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 196.8% above the current price.
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Next Reporting Date
- Expected Earnings per Share
- -0.35 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.27 | – | 0 | -3.40 | -6,385.40 | -14 | -14 |
| 2025: Q1 | -0.31 | – | 1 | 40.00 | -2,160.70 | -17 | -17 |
| 2025: Q2 | -0.32 | – | 1 | 7.50 | -2,316.10 | -16 | -16 |
| 2025: Q3 | -0.35 | – | 1 | -12.80 | -2,419.00 | -15 | -15 |
| 2025: Q4 | 0.10 | – | 31 | 12,120.20 | 20.20 | -2 | -2 |
| 2026: Q1 | -0.35 | – | 0 | -87.30 | -18,810.00 | -22 | -22 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
About the Company
Orchestra BioMed Holdings, Inc. ist ein biomedizinisches Unternehmen in den USA.
| Employees | 86 |
|---|---|
| Headquarters | New Hope, PA |
| Website | orchestrabiomed.com |
| IPO Date | 4. Aug 2020 |
Management
| Name | Title | Birth Year |
|---|---|---|
| David P. Hochman | Founder, Chairman of the Board of Directors & CEO | 1975 |
| Darren R. Sherman | Founder, President, COO & Director | 1971 |
| Andrew Lawrence Taylor M.B.A. | Chief Financial Officer | 1971 |
| William Reed Little | Executive Vice President of Corporate Development & Strategy | 1971 |
| Lisa Daniels | Vice President of Human Resources | – |
| Yuval Hay Mika D.Sc, Ph.D. | GM & CTO of Bioelectronic Therapies | 1959 |
| Hans-Peter Stoll M.D., Ph.D. | Senior VP & Medical Director | – |
| Avraham Matityahu Fischer M.D. | Senior Vice President of Medical Affairs & Innovation | 1956 |
| Bob Laughner | Senior Vice President of Regulatory & Quality | – |
| Juan Lorenzo | Senior Vice President of Product Development | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: August 3, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.